Phase 3 trial team-ET in 106 high-risk Essential Thrombocythemia patients, demonstrating non-inferiority of anathromb, a novel, extended-release anagrelide formulation, to the licensed comparator
Heinz Gisslinger(Medical University of Vienna), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Vera Yablokova, Krzysztof Warzocha(Instytut Hematologii i Transfuzjologi), Nikolay Tzvetkov(École Normale Supérieure de Lyon), Marek Hus(Medical University of Lublin), Tatyana Shneyder(Leningrad Regional Cancer Center), Juri Hodisch(AOP Orphan (Austria)), Kamil Kaplanov(Volgograd Regional Clinical Oncology Center), Janusz Kłoczko(University Clinical Hospital In Bialystok), Christoph Klade(Intercell (Austria)), Sławomira Kyrcz‐Krzemień(Medical University of Silesia), Atanas Radinoff(Tokuda Hospital), A. L. Melikyan(Endocrinology Research Center), Małgorzata Całbecka(Provincial Polyclinical Hospital in Toruń), Abdulkadyrov Km(Russian Research Institute of Hematology and Transfusiology), Mindaugas Jurgutis(Republic Klaipeda Hospital), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Elena Karyagina(City Hospital No. 40), Rolandas Gerbutavičius(Hospital of Lithuanian University of Health Sciences Kaunas Clinics)
Lithuanian University of Health Sciences
January 1, 2016
Cited by 0
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450